In this article, Markus Roggen demonstrates a new method for recapturing terpenes lost during the cannabis extraction process. Terpenes provide cannabis with distinctive aromas and flavors that are often desired by the consumer. During the cannabis drying and decarboxylation stages, up to 30% of…

The author spoke with Dr. Markus Roggen of Delic Labs, whose vape and smoke research involves a smoking machine that simulates how a person would inhale. The inhalation is captured and the contents are analyzed. Spoiler alert: toxic compounds are found.

The largest ketamine therapy provider in the U.S. has expanded its relationship with the Department of Veterans Affairs’ Community Care Network to provide more ketamine treatments for veterans suffering from a variety of depressive disorders.

The subsidiary of Delic Holdings Corp, Ketamine Wellness Centers (KWC) has further advanced its collaboration with the Veterans Administration Community Care Network (VA-CCN) to cover SPRAVATO treatments at certain clinics.

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country, and reframing the conversation on psychedelics. With the largest infrastructure of psychedelic wellness clinics in the U.S., Delic is making these affordable, effective….

Psychedelic drugs can induce mind-altering states affecting perception, thought and sensory input. They have historically been known for their recreational use and do not have nationwide legal approval. However, psychedelic drugs are also increasingly being studied for their medical benefits.

Nicholson said part of the aim of his company’s expansion is to make ketamine therapy more widely available. But he also admitted that another goal is to create a large footprint across the country in anticipation of the time when other, more potent, psychedelics might become F.D.A. approved.

This month, we spoke with Kevin Nicholson, CEO of Ketamine Wellness Centers and recently-announced CEO of Delic Corp., to discuss the future of ketamine research and why industry partnerships will be crucial to improving access.

Dr. Markus Roggen, the president and chief science officer of psychedelics and cannabis research and development firm Delic Labs, said he supports the intent of the San Francisco psychedelics proposal.

In yet another indication that lawmakers are continuing to step up their interest in psychedelics, Miriam Delphin-Rittmon, the assistant secretary for Mental Health and Substance Use, sent a letter to U.S. Rep. Madeleine Dean in May, saying that the Substance Abuse and Mental Health Services…